登陆
当前位置: 首页 >> 检索结果

结果排序

文献格式

出版时间

出版类型

出版语言
共有 4495 条符合本次的查询结果， 用时 5.5749813 秒

3721. Safety of Testosterone-Replacement Therapy in Older Men.

作者: Eric Orwoll.
来源: N Engl J Med. 2023年389卷2期177-178页

3722. Case 21-2023: A 61-Year-Old Man with Eyelid Swelling.

作者: Natalie Wolkow.;Laura V Romo.;Camille V Edwards.;Anna M Stagner.
来源: N Engl J Med. 2023年389卷2期166-175页

3723. Inguinal Erythrasma.

作者: Xiaopo Wang.
来源: N Engl J Med. 2023年389卷2期e4页

3724. Cutaneous Electroanalgesia for Relief of Chronic and Neuropathic Pain.

作者: Thomas J Smith.;Eric J Wang.;Charles L Loprinzi.
来源: N Engl J Med. 2023年389卷2期158-164页

3725. BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas.

作者: Priscilla K Brastianos.;Erin Twohy.;Susan Geyer.;Elizabeth R Gerstner.;Timothy J Kaufmann.;Shervin Tabrizi.;Brian Kabat.;Julia Thierauf.;Michael W Ruff.;Daniela A Bota.;David A Reardon.;Adam L Cohen.;Macarena I De La Fuente.;Glenn J Lesser.;Jian Campian.;Pankaj K Agarwalla.;Priya Kumthekar.;Bhupinder Mann.;Shivangi Vora.;Michael Knopp.;A John Iafrate.;William T Curry.;Daniel P Cahill.;Helen A Shih.;Paul D Brown.;Sandro Santagata.;Fred G Barker.;Evanthia Galanis.
来源: N Engl J Med. 2023年389卷2期118-126页
Craniopharyngiomas, primary brain tumors of the pituitary-hypothalamic axis, can cause clinically significant sequelae. Treatment with the use of surgery, radiation, or both is often associated with substantial morbidity related to vision loss, neuroendocrine dysfunction, and memory loss. Genotyping has shown that more than 90% of papillary craniopharyngiomas carry BRAF V600E mutations, but data are lacking with regard to the safety and efficacy of BRAF-MEK inhibition in patients with papillary craniopharyngiomas who have not undergone previous radiation therapy.

3726. At Breaking Point or Already Broken? The National Health Service in the United Kingdom.

作者: David J Hunter.
来源: N Engl J Med. 2023年389卷2期100-103页

3727. Solar Retinopathy.

作者: Joshua Taylor.;David C Sousa.
来源: N Engl J Med. 2023年389卷2期165页

3728. Medicare's Plan for Drug-Price Negotiation - The Importance of Defining Generic Entry.

作者: Stacie B Dusetzina.;Nancy L Keating.;Haiden A Huskamp.;Michelle M Mello.
来源: N Engl J Med. 2023年389卷2期97-100页

3729. Hospital Problems.

作者: Michael Putman.
来源: N Engl J Med. 2023年389卷2期103-105页

3730. Case 11-2023: A Man with Mantle-Cell Lymphoma and Hypoxemia. Reply.

作者: Samuel A Hofacker.;Eric P Schmidt.
来源: N Engl J Med. 2023年389卷1期95页

3731. Case 11-2023: A Man with Mantle-Cell Lymphoma and Hypoxemia.

作者: Anindya Gupta.
来源: N Engl J Med. 2023年389卷1期94-95页

3732. Screening for Prostate Cancer. Reply.

作者: Paul F Pinsky.;Howard Parnes.
来源: N Engl J Med. 2023年389卷1期94页

3733. Screening for Prostate Cancer.

作者: Joseph Presti.;Stacey Alexeeff.;Andrew L Avins.
来源: N Engl J Med. 2023年389卷1期93-94页

3734. Screening for Prostate Cancer.

作者: Kentaro Inamura.
来源: N Engl J Med. 2023年389卷1期93页

3735. Screening for Prostate Cancer.

作者: Jon Hoover.;Courtney Butterfass.;Ally Ponder.
来源: N Engl J Med. 2023年389卷1期92-93页

3736. Fifteen-Year Outcomes of the ProtecT Trial for Localized Prostate Cancer. Reply.

作者: Freddie C Hamdy.;Jenny L Donovan.
来源: N Engl J Med. 2023年389卷1期92页

3737. Fifteen-Year Outcomes of the ProtecT Trial for Localized Prostate Cancer.

作者: Matthew J Davis.;Alex Stephens.;Firas Abdollah.
来源: N Engl J Med. 2023年389卷1期90-92页

3738. Endovascular Thrombectomy for Acute Large Ischemic Strokes. Reply.

作者: Amrou Sarraj.;Deep K Pujara.;Bruce C Campbell.
来源: N Engl J Med. 2023年389卷1期89-90页

3739. Endovascular Thrombectomy for Acute Large Ischemic Strokes.

作者: Daniel P O Kaiser.
来源: N Engl J Med. 2023年389卷1期89页

3740. Endovascular Thrombectomy for Acute Large Ischemic Strokes.

作者: Baikuntha Panigrahi.
来源: N Engl J Med. 2023年389卷1期88-89页
共有 4495 条符合本次的查询结果， 用时 5.5749813 秒